HK1110338A1 - 專門用於癌症增殖細胞核抗原的異型體結合抗體及其用途 - Google Patents

專門用於癌症增殖細胞核抗原的異型體結合抗體及其用途

Info

Publication number
HK1110338A1
HK1110338A1 HK08104648.0A HK08104648A HK1110338A1 HK 1110338 A1 HK1110338 A1 HK 1110338A1 HK 08104648 A HK08104648 A HK 08104648A HK 1110338 A1 HK1110338 A1 HK 1110338A1
Authority
HK
Hong Kong
Prior art keywords
binding antibodies
cancer specific
isoform binding
pcna isoform
specific pcna
Prior art date
Application number
HK08104648.0A
Other languages
English (en)
Inventor
Robert J Hickey
Linda H Malkas
Lauren Schnaper
Original Assignee
Indiana Univ Res And Tech Corpora
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Indiana Univ Res And Tech Corpora filed Critical Indiana Univ Res And Tech Corpora
Publication of HK1110338A1 publication Critical patent/HK1110338A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Dispersion Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK08104648.0A 2005-04-27 2008-04-25 專門用於癌症增殖細胞核抗原的異型體結合抗體及其用途 HK1110338A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US67527505P 2005-04-27 2005-04-27
US68961405P 2005-06-09 2005-06-09
PCT/US2006/016096 WO2006116631A2 (en) 2005-04-27 2006-04-27 Cancer specific pcna isoform binding antibodies and uses thereof

Publications (1)

Publication Number Publication Date
HK1110338A1 true HK1110338A1 (zh) 2008-07-11

Family

ID=37215524

Family Applications (1)

Application Number Title Priority Date Filing Date
HK08104648.0A HK1110338A1 (zh) 2005-04-27 2008-04-25 專門用於癌症增殖細胞核抗原的異型體結合抗體及其用途

Country Status (10)

Country Link
US (4) US20080206140A1 (zh)
EP (1) EP1874823B1 (zh)
JP (1) JP2008539271A (zh)
AU (1) AU2006239318A1 (zh)
BR (1) BRPI0607676A2 (zh)
CA (1) CA2605745A1 (zh)
EA (1) EA200702361A1 (zh)
HK (1) HK1110338A1 (zh)
MX (1) MX2007013584A (zh)
WO (1) WO2006116631A2 (zh)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7294471B2 (en) * 2002-02-27 2007-11-13 Cskeys, Llc Method for purifying cancer-specific proliferating cell nuclear antigen
US8653039B2 (en) 2006-02-17 2014-02-18 Robert J. Hickey Peptide based inhibition of caPCNA interaction in cancer
CA3023068C (en) * 2008-07-24 2022-06-21 Indiana University Research And Technology Corporation Cancer peptide therapeutics
US20120195978A1 (en) * 2009-10-07 2012-08-02 Indiana University Research And Technology Corpora Capcna peptide therapeutics for cancer
US8455200B2 (en) 2009-10-15 2013-06-04 Traxxsson, Llc Measurement of PKA for cancer detection
EP2688566A4 (en) * 2011-03-23 2014-09-10 Univ Indiana Res & Tech Corp ANTICANCER THERAPEUTIC AGENTS
US10451633B2 (en) * 2014-03-24 2019-10-22 IMMCO Diagnostics, Inc. Anti-nuclear antibody detection and diagnostics for systemic and non-systemic autoimmune disorders
US10420840B2 (en) 2015-04-10 2019-09-24 Rll, Llc Anticancer therapeutic agents
IL267340B2 (en) * 2016-12-15 2023-12-01 Nat Inst Biotechnology Negev Ltd Monoclonal antibodies against PCNA and their use
CA3103629A1 (en) 2018-06-15 2019-12-19 Flagship Pioneering Innovations V, Inc. Increasing immune activity through modulation of postcellular signaling factors
EP3962493A2 (en) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor
JP2023509359A (ja) 2019-12-17 2023-03-08 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド 鉄依存性細胞分解の誘導物質との併用抗癌療法
CN116096906A (zh) 2020-06-29 2023-05-09 旗舰创业创新五公司 工程化以促进萨诺传递的病毒及其在治疗癌症中的用途
CA3214085A1 (en) 2021-03-31 2022-10-06 Darby Rye Schmidt Thanotransmission polypeptides and their use in treating cancer
KR20240026507A (ko) 2021-06-29 2024-02-28 플래그쉽 파이어니어링 이노베이션스 브이, 인크. 타노트랜스미션을 촉진시키도록 엔지니어링된 면역 세포 및 이의 용도
WO2024077191A1 (en) 2022-10-05 2024-04-11 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU750082B2 (en) * 1997-09-29 2002-07-11 University Of Maryland At Baltimore Altered DNA synthesome components as biomarkers for malignancy
US7294471B2 (en) * 2002-02-27 2007-11-13 Cskeys, Llc Method for purifying cancer-specific proliferating cell nuclear antigen
EP1998177A3 (en) * 2003-01-06 2009-02-18 Wyeth Compositions and methods for diagnosing and treating colon cancers
CN101632020B (zh) * 2006-09-13 2013-11-27 昂西免疫有限公司 改进的免疫测定方法

Also Published As

Publication number Publication date
EP1874823A2 (en) 2008-01-09
AU2006239318A8 (en) 2006-11-02
WO2006116631A3 (en) 2007-03-22
US20180362626A1 (en) 2018-12-20
EA200702361A1 (ru) 2008-04-28
WO2006116631A2 (en) 2006-11-02
EP1874823B1 (en) 2016-01-13
BRPI0607676A2 (pt) 2009-09-22
US20150259407A1 (en) 2015-09-17
US20120244076A1 (en) 2012-09-27
MX2007013584A (es) 2008-04-22
JP2008539271A (ja) 2008-11-13
CA2605745A1 (en) 2006-11-02
US20080206140A1 (en) 2008-08-28
US9006396B2 (en) 2015-04-14
AU2006239318A1 (en) 2006-11-02

Similar Documents

Publication Publication Date Title
HK1110338A1 (zh) 專門用於癌症增殖細胞核抗原的異型體結合抗體及其用途
IL272883A (en) Monoclonal antibodies and their uses
HK1218126A1 (zh) 抗體
IL222922A (en) Antibodies against neurophilin-1 and their use
IL235620A0 (en) sp35 antibodies and their uses
EP1907001A4 (en) ILT3 BONDING MOLECULES AND ITS USES
IL184659A0 (en) Antibody variants and uses thereof
AP2008004471A0 (en) Anti-Alpha2 Intergin antibodies and their uses
IL187710A0 (en) Anti-trkb monoclonal antibodies and uses thereof
IL184024A0 (en) Irta-5 antibodies and their uses
HK1121470A1 (en) Binding polypeptides and uses thereof
IL187503A0 (en) Stable and soluble antibodies
PT2343320T (pt) Anticorpos anti-gitr e as suas utilizações
EP1940466A4 (en) ANTI-ADDL MONOCLONAL ANTIBODIES AND THEIR USE
GB0503546D0 (en) Antibody
EP1846032A4 (en) LUCA2 AND ANTIBODY BINDING
ZA200709456B (en) Anti-IL2 antibodies
HK1107402A1 (en) Kid31 and antibodies that bind thereto kid31
ZA200801389B (en) II-6 Binding proteins
GB0502979D0 (en) Biomarkers and uses thereof
GB0426592D0 (en) Particle based binding assay
EP1915391A4 (en) SRA-BINDING PROTEIN
GB0502978D0 (en) Biomarkers and uses thereof
EP1881843A4 (en) KINASEPEPTIDES AND ANTIBODIES
GB0507272D0 (en) Antibody and uses thereof